Catalog No.
Product Name
Application
Product Information
Citations
-
ALDH1A Inhibitor
CM010 is a selective inhibitor of the aldehyde dehydrogenase 1A (ALDH1A) family, exhibiting IC50 values of 1700 nM, 740 nM, and 640 nM for ALDH1A1, ALDH1A2, and ALDH1A3, respectively. This compound does not inhibit other members of the ALDH family, making it a valuable tool for specific enzyme studies. CM010 demonstrates potential in regulating metabolic processes and exhibits anti-cancer activity, making it relevant for cancer research applications. -
Dehydrogenase
ALDH (Aldehyde dehydrogenase (NAD(P))) is an enzyme that catalyzes the oxidation of aldehydes into their corresponding carboxylic acids, simultaneously reducing the cofactors NAD(P) to NAD(P)H. This enzymatic activity is crucial for cellular detoxification and metabolism, making ALDH significant in biochemical research. It is frequently employed in studies investigating aldehyde stress responses and metabolic pathways related to aldehyde processing. -
ALDH1A3 Inhibitor
ALDH1A3-IN-2 is a selective inhibitor of aldehyde dehydrogenase 1A3 (ALDH1A3) with an IC50 of 1.29 μM. This compound demonstrates significant potential for studying the role of ALDH1A3 in various malignancies, particularly in prostate cancer where ALDHs are frequently overexpressed. ALDH1A3-IN-2 can be utilized in research focusing on cancer pathways and therapeutic strategies targeting ALDH-related enzymatic activity. -
ALDH1A3 Inhibitor
MCI-INI-3 is a selective competitive inhibitor of human ALDH1A3, exhibiting a Ki value of 0.55 μM for ALDH1A3 and a Ki value of 78.2 μM for ALDH1A1. This compound effectively disrupts retinoic acid biosynthesis, leading to a reduction in viability of glioblastoma stem cells GSC-83 and GSC-326. MCI-INI-3 is a valuable tool for research focused on cancer biology and the therapeutic targeting of glioblastoma. -
ALDH1A3 Inhibitor
KOTX1 is a selective inhibitor of the ALDH1A3 enzyme, demonstrating oral bioactivity. This compound has been shown to enhance glucose tolerance, promote insulin secretion, and regulate blood sugar levels in diabetic mouse models. KOTX1 is a valuable tool for investigating metabolic disorders and the role of ALDH1A3 in diabetes research. -
aldh1a1 Inhibitor
ALDH1A1-IN-2 is a selective inhibitor of aldehyde dehydrogenase 1A1 (ALDH1A1), an enzyme crucial for the oxidation of cytotoxic aldehydes. By inhibiting ALDH1A1, this compound may contribute to studies focusing on cancer, inflammation, and obesity-related pathways. Its biological activity positions it as a valuable tool for researchers investigating the roles of ALDH enzymes in diverse pathophysiological conditions. -
aldehyde dehydrogenase inhibitor
Nitrefazole is a 4-nitroimidazole derivative functioning as a potent inhibitor of aldehyde dehydrogenase (ALDH). It exhibits strong and sustained inhibition of ALDH, an enzyme critical in alcohol metabolism. This compound is valuable for research applications focused on alcoholism, metabolic studies, and pharmacological modulation of ALDH activity. -
Stable Isotope
4-Hydroxynonenal-d3 is a deuterated form of 4-Hydroxynonenal, an α,β-unsaturated hydroxyalkenal recognized as a biomarker for oxidative and nitrosative stress. It serves as both a substrate and an inhibitor of acetaldehyde dehydrogenase 2 (ALDH2), influencing various signaling pathways by forming covalent adducts with nucleophilic sites in proteins, nucleic acids, and membrane lipids. As a significant player in cancer biology, 4-Hydroxynonenal impacts mitochondrial function and cellular signaling processes, making it valuable for research in oxidative stress and its implications in disease. -
Aldehyde Dehydrogenase (ALDH) Inhibitor
S-Methyl-N,N-diethylthiolcarbamate is an effective inhibitor of aldehyde dehydrogenase (ALDH). This compound serves as the active metabolite of the aldehyde dehydrogenase inhibitor disulfiram, generated through the methylation of diethyldithiocarbamate in mouse liver microsomes. S-Methyl-N,N-diethylthiolcarbamate exhibits significant biological activity, demonstrated by its ability to inhibit rat liver low Km ALDH with an ID50 value of 15.5 mg/kg. In vivo studies indicate that a dose of 20.6 mg/kg can reduce mean arterial pressure and elevate heart rate in rats under ethanol stimulation, highlighting its potential applications in cardiovascular and metabolic research. -
ALDH1A2 Inhibitor
ALDH1A2-IN-1 is a reversible inhibitor targeting the active site of ALDH1A2, demonstrating an IC50 of 0.91 μM and a Kd of 0.26 μM. This compound is characterized by multiple hydrophobic interactions, making it an effective tool for studying the enzyme's role in biological pathways. It is applicable in research focused on cancer metabolism, stem cell differentiation, and neurotransmitter synthesis modulation. -
ALDH1 B1 Inhibitor
IGUANA-1 free base is a selective inhibitor of aldehyde dehydrogenase 1 B1 (ALDH1 B1) with an IC50 value of 30 nM. This compound demonstrates significant anti-proliferative activity against SW480 colorectal cancer cells, achieving IC50 values of 2.46 μM under adherent conditions and 0.39 μM in spheroid cultures. IGUANA-1 free base is a valuable tool for cancer research, particularly in studying the role of ALDH1 B1 in tumor growth and progression. -
ALDH-2/MAO Inhibitor
7-Hydroxy-4-phenylcoumarin is a dual inhibitor of aldehyde dehydrogenase-2 (ALDH-2) and monoamine oxidase (MAO), demonstrating IC50 values of 1.5 µM and 0.5 µM, respectively. This compound exhibits significant biological activity that may influence cellular metabolism and neurotransmitter regulation. It is suitable for research applications focused on neuroprotection and metabolic studies. -
ALDH2 Agonist
ALDH2 activator 1 is an allosteric agonist of aldehyde dehydrogenase 2 (ALDH2). This compound enhances cardiac function and mitigates myocardial necrosis in murine models of myocardial ischemia-reperfusion. It holds potential for advancing research in cardiovascular diseases, particularly in the context of myocardial infarction. -
ALDH Enhancer
Taraxerone is an ALDH enhancer derived from Sedum sarmentosum. It significantly increases the activities of alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH), exhibiting EC50 values of 512.42 μM and 500.16 μM, respectively. This compound is valuable for studies focused on alcohol metabolism and enzyme regulation in biochemical research. -
ALDH1A1 Inhibitor
FSI-TN42 is a selective, irreversible inhibitor of ALDH1A1 with an IC50 of 23 nM, demonstrating significant potency with an 800-fold preference over ALDH1A2. This compound is valuable for research applications targeting metabolic pathways involving aldehyde dehydrogenases, particularly in cancer and stem cell studies. Its oral bioavailability makes it a suitable candidate for in vivo investigations of ALDH1A1's role in various biological processes. -
Acetaldehyde Dehydrogenase Inhibitor
Coprine is a mycotoxin derived from Coprinopsis atramentaria that functions as an inhibitor of acetaldehyde dehydrogenase. By inhibiting this enzyme, coprine leads to the accumulation of acetaldehyde, which can trigger the alcohol flushing reaction in susceptible individuals. This compound is useful in research focused on alcohol metabolism and the effects of acetaldehyde accumulation on physiological processes. -
Aldehyde Dehydrogenase 2 Activator
Mirivadelgat is an activator of aldehyde dehydrogenase 2 (ALDH2), which plays a crucial role in detoxifying aldehydes and maintaining cellular homeostasis. This compound exhibits potential biological activity in the investigation of interstitial lung disease, pulmonary hypertension, and various cancer models. Mirivadelgat serves as a valuable tool for researchers studying metabolic pathways and therapeutic approaches related to these conditions. -
ALDH1A1 Inhibitor
ALDH1A1-IN-4 is a potent inhibitor of aldehyde dehydrogenase (ALDH) A1, demonstrating an IC50 value of 0.32 μM. This compound is significant in cancer research, offering insights into pathways involving ALDH1A1's role in tumor biology and potential therapeutic strategies. Its inhibitory activity may contribute to the understanding of cancer metabolism and the development of novel treatments. -
ALDH1A2 Inhibitor
CM121 is a reversible inhibitor of ALDH1A2, featuring a competitive mechanism with an IC50 of 0.54 μM and a Kd of 1.1 μM. This compound demonstrates significant hydrophobic interactions at the active site, making it a valuable tool for studying ALDH1A2's role in various biological processes. It is suitable for applications in cancer research and stem cell biology, where modulation of aldehyde dehydrogenase activity is of interest. -
Acohol use disorder
Lefelsiran is a small interfering RNA (siRNA) that specifically targets aldehyde dehydrogenase 2 (ALDH2). This reagent is primarily employed in research focused on alcohol use disorder, investigating the molecular mechanisms underlying this condition. By modulating ALDH2 expression, Lefelsiran facilitates the study of its role in alcohol metabolism and the potential therapeutic interventions for alcohol dependence. -
ALDH1A1 Inhibitor
ALDH1A1-IN-3 is a selective inhibitor of aldehyde dehydrogenase 1A1 (ALDH1A1), demonstrating an IC50 value of 0.379 μM. This compound effectively enhances glucose consumption in HepG2 cells, making it a valuable tool for studying glucose metabolism. ALDH1A1-IN-3 is suitable for research applications focused on metabolic regulation and potential therapeutic interventions in metabolic disorders. -
ALDH Inhibitor
Aldi-2 is a selective covalent inhibitor of aldehyde dehydrogenases (ALDHs), exhibiting IC50 values of 2.5, 6.4, and 1.9 μM for ALDH1A1, ALDH2, and ALDH3A1, respectively. This compound is particularly valuable in cancer research, providing insight into the role of ALDHs in tumor metabolism and progression. Its specificity allows for targeted studies on the modulation of ALDH activity within various biological contexts. -
Aldehyde Dehydrogenase (ALDH) Inhibitor
CM026 is a selective inhibitor of aldehyde dehydrogenase 1A1 (ALDH1A1), demonstrating submicromolar potency. The compound exerts its inhibitory effect through binding to the aldehyde binding pocket, specifically involving a unique glycine residue. CM026 serves as a valuable chemical tool for investigating the role of ALDH1A1 in various pathological conditions and studying its implications in disease research. -
ALDH2 modulator
ALDH2 Modulator 1 is a potent modulator of aldehyde dehydrogenase-2 (ALDH2), showcasing effective oral bioavailability. This compound has been demonstrated to significantly reduce blood alcohol levels in murine models, highlighting its potential applications in alcohol metabolism research and related metabolic studies. -
ALDH3A1 Inhibitor
ALDH3A1-IN-4 is a selective inhibitor of ALDH3A1, exhibiting an IC50 of 0.2 μM. This compound interacts with the aldehyde-binding pocket of ALDH3A1 through hydrophobic interactions and van der Waals forces. ALDH3A1-IN-4 functions as a chemosensitizer, enhancing the antiproliferative effects of mafosfamide in ALDH3A1-expressing cancer cells while sparing non-cancer cells. It is particularly relevant for research on lung adenocarcinoma and glioblastoma. -
ALDH1A1 Inhibitor
NCT-501 hydrochloride is a highly potent and selective inhibitor of aldehyde dehydrogenase 1A1 (ALDH1A1), demonstrating an IC50 of 40 nM. It exhibits superior selectivity against other ALDH isozymes, as well as various dehydrogenases, with IC50 values greater than 57 μM for hALDH1B1, hALDH3A1, and hALDH2. This compound is valuable for research applications focused on cancer biology, neurodegenerative diseases, and other conditions where ALDH1A1 activity plays a critical role. -
ALDH3A1 Inhibitor
ALDH3A1-IN-2 is a potent inhibitor of aldehyde dehydrogenase 3A1 (ALDH3A1) with an IC50 of 1.29 μM. This compound is particularly relevant for research in oncology, as ALDHs, including ALDH3A1, are often overexpressed in various tumor types, such as prostate cancer. ALDH3A1-IN-2 may provide valuable insights into the role of ALDH3A1 in cancer progression and therapeutic intervention. -
ALDH Inhibitor
GA11 is an inhibitor of aldehyde dehydrogenase (ALDH), demonstrating significant anti-glioblastoma activity in both in vitro and in vivo models. This compound is valuable for research applications focusing on cancer biology and therapeutic strategies targeting glioblastoma through ALDH modulation. -
ALDH1A1 Modulator
ALDH1A1 modulator-1 is a selective modulator of the aldehyde dehydrogenase 1A1 (ALDH1A1) enzyme. This compound exhibits the ability to influence ALDH1A1 activity, which plays a critical role in the detoxification of aldehydes and the metabolic regulation of retinoic acid. ALDH1A1 modulator-1 is valuable for research focused on cancer biology, stem cell differentiation, and metabolic disorders, providing insights into the modulation of ALDH1A1 in various biological contexts. -
ALDH Inhibitor
CM-39 is a non-covalent, reversible inhibitor of aldehyde dehydrogenase 1A (ALDH1A), exhibiting an IC50 of 0.9 μM. This compound is used in research applications focusing on the modulation of cellular aldehyde metabolism and the study of cancer biology, where ALDH1A plays a significant role in stem cell regulation and chemoresistance. It provides a valuable tool for scientists investigating the therapeutic potential of targeting ALDH pathways in various disease models. -
PKM2 Inhibitor
PKM2-IN-7 is a selective inhibitor of pyruvate kinase M2 (PKM2) that disrupts the interaction between PKM2 and ALDH1A3, demonstrating minimal toxicity to normal cells. This compound is pivotal for investigations into tumor biology, making it an essential tool for research focused on cancer metabolism and tumorigenesis. -
NNMT Inhibitor
JBSNF-000028 free base is a potent inhibitor of nicotinamide N-methyltransferase (NNMT), exhibiting IC50 values of 33 nM, 210 nM, and 190 nM for human, mouse, and monkey NNMT, respectively. This compound effectively reduces endogenous MNA levels in U2OS osteosarcoma cells, with an EC50 of 2.5 μM. JBSNF-000028 free base demonstrates notable anti-obesity and anti-diabetic effects in diet-induced obesity models, making it a valuable tool for researching metabolic disorders, including obesity, type 2 diabetes, and non-alcoholic fatty liver disease. -
NNMT Inhibitor
NCGC00685960 is a potent inhibitor of Nicotinamide N-methyltransferase (NNMT) with an IC50 value of less than 10 nM. This compound exhibits significant antitumor properties by enhancing H3K27 trimethylation levels in ovarian cancer cells and reducing α-SMA expression in NNMT-expressing ovarian fibroblasts. Additionally, NCGC00685960 lowers 1-MNA levels and reverses SAM and H3K27 hypomethylation, effectively diminishing collagen contractility in cancer-associated fibroblasts (CAFs). It is a valuable reagent for cancer research applications. -
NNMT Inhibitor
MS2734 is a potent inhibitor of nicotinamide N-methyltransferase (NNMT), exhibiting an IC50 value of 14 μM against human NNMT (hNNMT). This compound effectively disrupts the methyltransferase activity of NNMT, making it a valuable tool for investigating the role of NNMT in metabolic disorders, neurodegenerative diseases such as Parkinson's disease, and various cancers characterized by elevated NNMT levels. Its utility in research applications extends to the exploration of obesity and diabetes-related mechanisms. -
NNMT Inhibitor
NNMT-IN-6 hydrochloride is a potent inhibitor of nicotinamide N-methyltransferase (NNMT), exhibiting an IC50 value of 1.41 μM and a Kd of 5.6 μM. This compound demonstrates significant inhibitory effects on the proliferation of the HSC-2 human oral cancer cell line, making it a valuable tool for research in cancer biology and NNMT-related pathways. Its ability to modulate NNMT activity may provide insights into therapeutic strategies for diseases associated with altered methylation processes. -
NNMT Inhibitor
NNMT-IN-3 is a highly potent and selective inhibitor of nicotinamide N-methyltransferase (NNMT), exhibiting IC50 values of 1.1 nM in cell-free assays and 0.4 μM in cell-based assays. This compound plays a critical role in studying metabolic disorders and can be utilized in research involving obesity, type 2 diabetes, and cancer. Its specific inhibition of NNMT allows for detailed exploration of the enzyme's involvement in these significant diseases. -
NNMT Inhibitor
II399 is a potent and selective inhibitor of nicotinamide N-methyltransferase (NNMT), featuring an unconventional S-adenosylmethionine (SAM) mimic, with a Ki value of 5.9 nM. This compound shows competitive inhibition for nicotinamide (NAM) by binding to both substrate and cofactor binding sites. II399 is valuable for research applications in cancer, metabolic disorders, cardiovascular diseases, and neurodegenerative conditions. -
NNMT Inhibitor
4-Chloropyridine is an inhibitor of Nicotinamide N-methyltransferase (NNMT), functioning as a substrate and a precursor for suicide inhibition-based protein labeling. This compound enhances the C4 electrophilicity of pyridine nitrogen through NNMT-catalyzed methylation, allowing for aromatic nucleophilic substitution at cysteine C159, resulting in covalent modification and inactivation of NNMT. 4-Chloropyridine is valuable for research into various cancers, facilitating studies on the role of NNMT in tumor biology. -
NNMT Inhibitor
NNMT-IN-6 is a potent inhibitor of nicotinamide N-methyltransferase (NNMT), exhibiting an IC50 value of 1.41 μM and a dissociation constant (Kd) of 5.6 μM. This compound effectively inhibits cell proliferation in the HSC-2 human oral cancer cell line, making it a valuable tool for research focused on cancer biology and metabolism. Its specificity towards NNMT positions it as a promising candidate for further studies in therapeutic applications targeting NNMT-related pathways. -
NNMT Inhibitor
NNMT-IN-7 is a potent inhibitor of nicotine and nicotine metabolism transferase (NNMT) with an IC50 of 505.7 µM. This compound serves as a valuable tool for investigating the role of NNMT in metabolic and chronic diseases. Its use in research may provide insights into therapeutic strategies targeting metabolic disorders linked to altered NNMT activity. -
FXR Agonist
HPG1860 is a highly selective and potent agonist of the farnesoid X receptor (FXR), demonstrating an EC50 of 18 nM in FXR-luciferase reporter assays. This compound exhibits minimal activity on TGR5 and 13 other related nuclear receptors, with EC50 values exceeding 30.0 μM. HPG1860 is primarily utilized in research investigating non-alcoholic steatohepatitis (NASH) and related metabolic disorders. -
Hydrolase Enzyme
α-Amylase is a hydrolase enzyme that facilitates the hydrolysis of internal α-1,4-glycosidic linkages in starch, producing glucose and maltose as key products. This enzyme plays a critical role in carbohydrate metabolism and is widely used in biochemical research to study starch degradation and enzymatic activity. Its applications extend to food science, biotechnology, and various analytical methods in the life sciences. -
α-amylases Substrate
Maltopentaose is a substrate for α-amylases, serving as the shortest chain oligosaccharide. This compound is classified as maltodextrin and is instrumental in studies examining glycation and phosphorylation of α-lactalbumin. Additionally, maltopentaose facilitates the investigation of inhibition kinetics in human pancreatic α-amylase by compounds such as dehydrodieugenol B, making it valuable for enzyme kinetics and carbohydrate-related research. -
Antioxidant
Acetylregaloside C is a natural antioxidant derived from Madonna Lily (Lilium candidum L.). This compound enhances the activity of α-amylase, which is essential in carbohydrate metabolism. Acetylregaloside C is useful in research applications focused on oxidative stress and metabolic disorders, contributing to the understanding of its potential therapeutic effects. -
α-Amylase/α-Glucosidase Inhibitor
α-Amylase/α-Glucosidase-IN-23 is a potent inhibitor of α-amylase and α-glucosidase, demonstrating IC50 values of 73.68 nM and 146.18 nM, respectively. This compound is valuable for research focused on glucose metabolism and the management of hypoglycemia. Its ability to inhibit carbohydrate-hydrolyzing enzymes makes it a useful tool for studies investigating glycemic control and related metabolic disorders. -
α-Amylase Substrate
Ethylidene-4-nitrophenyl-α-D-maltoheptaoside serves as a substrate for α-amylase, facilitating the assessment of enzyme activity. Upon degradation by α-amylase, along with auxiliary enzymes like α-glucosidase, it releases a chromophore that enables quantification of amylase activity. This reagent is particularly valuable in the diagnosis of pancreatitis and other related disorders. -
Amylase
Bacterial α-Amylase targets and hydrolyzes internal α-1,4-glycosidic linkages in starch, producing low molecular weight products such as glucose, maltose, and maltotriose. This enzyme plays a crucial role in carbohydrate metabolism and is widely utilized in biochemical studies to understand starch biodegradation and enzymatic processes. Its action is fundamental in various applications, including food science and research on metabolic pathways. -
α-Glucosidase Inhibitor
Quinoline-2-carboxylic acid functions as an α-glucosidase inhibitor, demonstrating significant potential in the modulation of glucose metabolism. This compound is of interest for its antidiabetic properties and serves as a valuable intermediate for the synthesis of various biologically active compounds in chemical research. Its role in enzyme inhibition makes it a relevant agent for studies aimed at understanding carbohydrate metabolism and diabetes management. -
Amylase
α-Amylase from Aspergillus oryzae is an enzyme that catalyzes the hydrolysis of starch into simpler sugars, primarily maltose and glucose. This reagent exhibits significant activity in breaking down complex carbohydrates, making it valuable for various biochemical studies, including carbohydrate metabolism and enzymatic kinetics. It serves as an essential tool in food science, biotechnology, and clinical research applications where starch-related processes are investigated. -
α-amylase Inhibitor
Chinese gallotannin is a non-specific α-amylase inhibitor, exhibiting a Ki of 0.82 μg/mL against human salivary α-amylase. This compound demonstrates potential biological activity in modulating starch digestion and may be useful in diabetes research. Its inhibition of α-amylase activity positions it as a candidate for studying carbohydrate metabolism and metabolic disorders.
